Your fact-checks will appear here
Long-term effects of repeated ivermectin dosing for parasitic diseases
Ivermectin is FDA‑approved for a small set of parasitic indications in humans—oral tablets for certain internal worms and topical formulations for external parasites and some skin conditions—but it is...
Ivermectin can cause common, usually mild adverse effects such as headache, nausea, dizziness, diarrhea, and skin rash when given at approved human doses . Serious but rare harms include neurological ...
Ivermectin dosing for human parasitic infections is weight-based, most commonly prescribed at about 200 micrograms per kilogram (mcg/kg) as a single oral dose for strongyloidiasis and many scabies reg...
Ivermectin dosing in humans is disease-specific and weight‑based: standard microgram-per-kilogram regimens range from about 150–200 µg/kg for onchocerciasis, strongyloidiasis and enterobiasis, to 400 ...
Ivermectin dosing is weight‑based, typically calculated in micrograms per kilogram and most often given as a single oral dose; common regimens for human parasitic infections fall between about 150 and...
Ivermectin dosing for human parasitic infections is weight-based and generally expressed in micrograms per kilogram (mcg/kg); the usual therapeutic range for common infections is about 150–200 mcg/kg ...
A focused search of the recent reporting and trial registries shows a small, active clinical program testing ivermectin in combination with immunotherapy for metastatic triple‑negative breast cancer —...
Short-term ivermectin use at approved doses is generally associated with mild, self-limited effects — dizziness, headache, gastrointestinal upset, and transient skin reactions — while rare but serious...
Poison control centers across the United States reported a clear rise in human ivermectin exposure calls beginning in late 2020 and accelerating in 2021, with national and state-level data showing mul...
Human safety data for subcutaneous (SC) or intramuscular (IM) ivermectin intended for injection are extremely limited: a handful of case reports and small pharmacokinetic observations describe compass...
Multiple marketed veterinary ivermectin formulations explicitly list clorsulon as a co‑active on their labels — commonly sold under names like IVOMEC Plus, Ivermax® Plus, Noromectin® Plus, Vetrimec™ P...
Published human case reports do include numeric measurements of ivermectin in cerebrospinal fluid (CSF): at least one peer‑reviewed case reported a CSF ivermectin concentration of 0.14 ng/mL with an a...
Ivermectin commonly interacts with drugs that affect CYP3A4 metabolism and P‑glycoprotein (P‑gp) transport, and with substances that add central‑nervous‑system (CNS) depression or alter bleeding risk;...
Poison control centers and emergency departments documented a clear uptick in human exposures to ivermectin during the COVID-19 era, with multiple case series and surveillance projects showing that ma...
Randomized trials testing ivermectin above 400 µg/kg do exist — most notably the COVER dose‑finding trial (600 and 1200 µg/kg arms), the ACTIV‑6 platform trial with a 600 µg/kg‑per‑day arm, and at lea...
A patchwork of randomized trials has evaluated ivermectin’s short‑term effects, but few registered RCTs explicitly set out to study long‑term safety; when long‑term endpoints are declared they most co...
Randomized and observational studies have tested five‑day ivermectin regimens almost exclusively in the context of COVID‑19, producing a patchwork of contradictory results: small trials from Banglades...
High-quality randomized controlled trials (RCTs) and comprehensive reviews paint a conflicted picture: several rigorous RCTs show no clear clinical benefit of ivermectin for COVID-19, while multiple m...